Objective:To develop the Scale of Pain-Relevant Responses from Spouse for Chronic Pain Patients and to test its reliability and validity, so as to provide a reliable tool for the scientific assessment of the pain-relevant responses from spouses for chronic pain patients.Methods:Based on the interpersonal process model of intimacy, the first draft of the scale was formed through literature analysis, semi-structured interview, Delphi expert consultation and pre-investigation. A questionnaire survey was conducted on 388 patients with chronic pain who visited the Second Affiliated Hospital of Air Force Military Medical University from April 2022 to April 2023 using convenience sampling method to test the reliability and validity of the scale.Results:The Scale of Pain-Relevant Responses from Spouse for Chronic Pain Patients included 21 items in 4 dimensions: emotional support pain-relevant responses, behavioral support pain-relevant responses, distractive pain-relevant responses and negative pain-relevant responses. The range of I-CVI was 0.850-1.000. The results of structural validity analysis showed that four qualified common factors were extracted by exploratory factor analysis, and the cumulative variance contribution rate was 71.173%. The confirmatory factor analysis model fit indicators were within the acceptable range. The correlation validity coefficient was 0.692 ( P<0.01). The Cronbach α coefficient of the total table was 0.894, the half reliability was 0.906, and the retest reliability was 0.927. Conclusions:The Scale of Pain-Relevant Responses from Spouse for Chronic Pain Patients has good reliability and validity, and is suitable for the evaluation of pain-relevant responses from spouse of chronic pain patients.

Objective:To investigate the influencing factors of learned helplessness in patients with primary liver cancer treated by interventional therapy.Methods:This study was a cross-sectional study. The 221 patients with primary liver cancer treated by interventional therapy in the Second Affiliated Hospital of Air Force Military Medical University from August 2020 to October 2021 were selected as the subjects. General data statistics, Learned Helplessness Scale and Support in Intimate Relationships Rating Scale were used for questionnaire survey.Results:The total score of learned helplessness in the 221 patients with primary liver cancer treated by interventional therapy was 74.12 ± 6.55. Gender, education level, family per capita monthly income, number of interventions and perceived spouse support were the main influencing factors of learned helplessness in patients with primary liver cancer treated by interventional therapy (adjusted R2=0.891, F=65.65, P<0.05). Conclusions:The sense of learned helplessness of patients with primary liver cancer treated by interventional therapy is at a high level. According to patients with features of male, lower education level, lower family per capita monthly income, more number of interventional therapy or lower perceived spouse support, medical staff can use dialectical behavior therapy, symptom group intervention, spouse support intervention and other methods to reduce learned helplessness of patients.

Histone lysine specific demethylase 1 (LSD1) has been recognized as an important modulator in post-translational process in epigenetics. Dysregulation of LSD1 has been implicated in the development of various cancers. Herein, we report the discovery of the hit compound (IC = 3.93 μmol/L) and further medicinal chemistry efforts, leading to the generation of compound (IC = 49 nmol/L, and = 16 nmol/L), which inhibited LSD1 reversibly and competitively with H3K4me2, and was selective to LSD1 over MAO-A/B. Docking studies were performed to rationalize the potency of compound . Compound also showed strong antiproliferative activity against four leukemia cell lines (OCL-AML3, K562, THP-1 and U937) as well as the lymphoma cell line Raji with the IC values of 1.79, 1.30, 0.45, 1.22 and 1.40 μmol/L, respectively. In THP-1 cell line, significantly inhibited colony formation and caused remarkable morphological changes. Compound induced expression of CD86 and CD11b in THP-1 cells, confirming its cellular activity and ability of inducing differentiation. The findings further indicate that targeting LSD1 is a promising strategy for AML treatment, the triazole-fused pyrimidine derivatives are new scaffolds for the development of LSD1/KDM1A inhibitors.